Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients
Rabia Ali, A., Mohamed Rabea, A., Ali Abdelkareem, S., Elsayed Sheir, R. (2021). Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients. EKB Journal Management System, 2(2), 7-19. doi: 10.21608/ejmr.2021.174195
Abdelrahman Rabia Ali; Alaa Mohamed Rabea; Shimaa Ali Abdelkareem; Rania Elsayed Sheir. "Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients". EKB Journal Management System, 2, 2, 2021, 7-19. doi: 10.21608/ejmr.2021.174195
Rabia Ali, A., Mohamed Rabea, A., Ali Abdelkareem, S., Elsayed Sheir, R. (2021). 'Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients', EKB Journal Management System, 2(2), pp. 7-19. doi: 10.21608/ejmr.2021.174195
Rabia Ali, A., Mohamed Rabea, A., Ali Abdelkareem, S., Elsayed Sheir, R. Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients. EKB Journal Management System, 2021; 2(2): 7-19. doi: 10.21608/ejmr.2021.174195

Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients

Egyptian Journal of Medical Research
Article 1, Volume 2, Issue 2 - Serial Number 1, June 2021, Page 7-19  XML PDF (385.3 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2021.174195
View on SCiNiTO View on SCiNiTO
Authors
Abdelrahman Rabia Ali1; Alaa Mohamed Rabea1; Shimaa Ali Abdelkareem2; Rania Elsayed Sheir1
1Internal Medicine Department, Beni-Suef University
2Clinical and Chemical Department Beni-Suef University.
Abstract
Background: Transcription factor 7-like 2 (TCF7L2) gene polymorphisms are known risk factors for type 2 diabetes mellitus (T2DM). However, the relationship between TCF7L2 polymorphism and diabetic nephropathy (DN) is inconclusive. Objectives: to explore the association of TCF7L2 rs7903146 (C/T) gene polymorphism and DN in T2DM  Egyptian patients. Methods: 80 patients with T2DM (40 patients without DN and 40 patients with DN) were enrolled in the study. Genotyping for the rs7903146 (C/T) polymorphism in TCF7L2 gene was performed by real time PCR.
Results: The frequency of rs7903146 genotypes in diabetic patients without DN was ( CC: 57.5%; CT: 37.5%; TT: 5%), while in diabetic patients with DN was (CC: 2.5%; CT: 40%; TT: 57.5%). Patients with DN were exposed to the TT 25.7 times more than who didn’t develop DN  (OR= 25.7, 95% CI= 0.43-94, P= 0.001**). Upon examining the allelic discrimination, C allele was present in 77.5%  of patients without DN versus 23.8%  of patients with DN, While T allele was found in 22.5%  of patients without DN versus 76.3%  of patients with DN. Patients with DN were exposed to the T allele  11 times more than who didn’t develop nephropathy (OR=11, 95% CI= 5.3-23.1 , P=<0.001**). Conclusion: rs7903146 TCF7L2 gene polymorphism may be significantly associated with the susceptibility to DN in Egyptian T2DM patients.
Keywords
Type 2 diabetes mellitus; diabetic nephropathy; TCF7L2 gene; rs7903146; polymorphism; Egypt
References
  1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.  Diabetes Res Clin Pract. 2019 Nov;157:107843.
  2. Tong Y1, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B . Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. Review article. BMC Med Genet. 2009 Feb 19;10:15.
  3. Grant SFA. The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes. Diabetes Care. 2019 Sep;42(9):1624-1629.
  4. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018;50:1505–1513.
  5. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881–885.
  6. Duval A, Busson LM, Berger R. Assignment of the TCF-4 gene (TCF7L2) to human chromosome band 10q25.3. Cytogenet Cell Genet 2000; 88:264–265.
  7. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320–323.
  8. Mitchell RK, Mondragon A, Chen L, et al. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum Mol Genet 2015; 24:1390–1399.
  9. Prunier C, Hocevar BA, Howe PH. Wnt signaling: physiology and pathology. Growth Factors. 2004;22:141–150.
  10. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem. 2005;280:1457–1464.
  11. Wang X, Xiao Y, Mou Y, et al. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res 2002;90:340–7.
  12. Lavoz C, Rayego-Mateos S, Orejudo M, Opazo-Ríos L, et al.  Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy? Review article. J Clin Med. 2020 Jan 19;9(1).
  13. Podgórski P, Konieczny A, Lis Ł, Witkiewicz W, Hruby Z.  Glomerular podocytes in diabetic renal disease.  Adv Clin Exp Med. 2019 Dec;28(12):1711-1715.
  14. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochemical and Biophysical Research Communications. 2013;433:359–361.
  15. Brosius FC, III, Khoury CC, Buller CL, Chen S. Abnormalities in signaling pathways in diabetic nephropathy. Expert Review of Endocrinology and Metabolism. 2010;5(1):51–64.
  16. Tang YL, Dong XY, Zeng ZG, Feng Z. Gene expression-based analysis identified NTNG1 and HGF as biomarkers for diabetic kidney disease. Medicine (Baltimore). 2020 Jan;99(1):e18596.
  17. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26(11): 3160-7.
  18. Pavlov V1, Xiao Y, Gill R, Dishon A, Kotler M, Willner I. Amplified chemiluminescence surface detection of DNA and telomerase activity using catalytic nucleic acid labels. Anal Chem. 2004 Apr 1;76(7):2152-6.
  19. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochemical and Biophysical Research Communications. 2013;433:359–361.
  20. Wang Y, Li H, Song SP. β-Arrestin 1/2 Aggravates Podocyte Apoptosis of Diabetic Nephropathy via Wnt/β-Catenin Pathway. Med Sci Monit. 2018 Mar 24;24:1724-1732.
  21. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/ β-catenin signaling promotes renal interstitial fibrosis. Journal of the American Society of Nephrology. 2009;20(4):765–776.
  22. El-Lebedy D, Ashmawy I.  Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.  J Genet Eng Biotechnol. 2016 Dec;14(2):247-251.
  23. Mandour I, Darwish R, Fayez R, Naguib M, El-Sayegh S. TCF7L2 Gene Polymorphisms and Susceptibility to Type 2 Diabetes Mellitus , A Pilot Study. Biomed Pharmacol J 2018; 11(2): 1043-9.
  24. Zhuang Y, Niu F, Liu D, Sun J, Zhang X, Zhang J, Guo S. Associations of TCF7L2 gene polymorphisms with the risk of diabetic nephropathy: A case-control study. Medicine (Baltimore). 2018 Oct;97(40):e8388.
  25. Fan Z, Cai Q, Chen Y, et al. Association of the Transcription Fac- tor 7 Like 2 (TCF7L2) Polymorphism With Diabetic Nephropathy Risk: A Meta-Analysis. Medicine (Baltimore). 2016; 95(11)e3087.
  26. Hussain H, Ramachandran V, Ravi S, et al. TCF7L2 rs7903146 polymorphism and diabetic nephropathy association is not independent of type 2 diabetes—a study in a south Indian population and meta-analysis. Endokrynol Polska 2014;65:298–305.
  27. Buraczynska M, Swatowski A, Markowska-Gosik D, et al. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and complication/comorbidity profile in type 2 diabetes patients. Diabet Res Clin Pract 2011;93:390–5.
  28. Buraczynska M, Zukowski P, Ksiazek P, et al. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and clinical phenotype in end-stage renal disease patients. Mol Biol Rep 2014;41:4063–8.
  29. Jin T. Current understanding on role of the Wnt signaling pathway effector TCF7L2 in glucose homeostasis. Endocrine reviews 2016; 37: 254-277.
  30. Xiao L, Wang M, Yang S, Liu F, Sun L. A glimpse of the pathogenetic mechanisms of Wnt/β-catenin signaling in diabetic nephropathy.  Biomed Res Int. 2013;2013:987064.
  31. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009 Nov;24(11):3360-6.
  32. Köttgen A, Hwang S-J, Rampersaud E, et al. TCF7L2 variants associate with CKD progression and renal function in population- based cohorts. J Am Soc Nephrol. 2008; 19(10): 1989- 99.
  33. Takada I, Makishima M. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present). Review article. Expert Opin Ther Pat. 2020 Jan;30(1):1-13.
  34. Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, Papanas N, Manolopoulos VG, Chatzaki E. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. Exp Clin Endocrinol Diabetes. 2019 Apr;127(4):226-233.
Statistics
Article View: 507
PDF Download: 346